Dementia and Alzheimer Disease

Epilepsy

Headache and Migraine

Movement Disorders

Multiple Sclerosis

Neuromuscular

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

International Journal of MS Care

Resources

Disease Spotlight

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

eNewsletter

Print Subscription

Articles

Preclinical findings show the potential of samelisant, a potent and orally active Histamine H3 receptor inverse agonist, as a potential treatment for patients with Parkinson disease who experience excessive daytime sleepiness. 

Samelisant Shows Potential as a Treatment for Excessive Daytime Sleepiness in Parkinson Disease

According to a recent study presented at SLEEP 2023, the decline in MOCA scores in patients with mild cognitive impairment was associated with the degree of hypoxia observed from sleep studies. 

Lower Oxygen Levels in Obstructive Sleep Apnea Associated With Worsening Mild Cognitive Impairment and Alzheimer Disease

Videos

The course directors of the 2023 ATRMD Congress provided an overview of the upcoming meeting, and the educational benefits clinicians can gain from attending. [WATCH TIME: 6 minutes]

Reasons to Attend the 2023 Advanced Therapeutics in Movement & Related Disorders Congress: Fernando Pagan, MD; Yasar Torres-Yaghi, MD

The chief medical officer of Harmony Biosciences provided perspective on a proof-of-concept study assessing pitolisant’s (Wakix) clinical benefit in reducing excessive daytime sleepiness individuals with Prader-Willi syndrome. 

NeuroVoices: Kumar Budur, MD, on Pitolisant’s Impact in Excessive Daytime Sleepiness, Prader-Willi Syndrome

Vice Chairman, Department of Neurology; Director, Movement Disorders Program; 

Medical Director, Georgetown University Hospital National Parkinsonism Foundation Center of Excellence; 

Medical Director, Translational Neurotherapeutics Program; 

Associate Professor, Department of Neurology, Georgetown University

, has been with the team since September 2022. Follow her on Twitter 

Carolyn H. Goldschmidt, DO, a neurologist at NorthShore University Health System in Chicago, talked about a retrospective study analyzing disease-modifying therapies in multiple sclerosis patients at CMSC 2023.

Bridging the Gap, De-Escalation of MS Disease Modifying Therapies: Carolyn H Goldschmidt, DO

Neurologist, Oregon Health State University

The professor of neurology at Oregon Health & Science University talked about a study on a modified low-fat diet intervention and its effects on fatigue in patients with multiple sclerosis over a 16-week period at CMSC 2023. [WATCH TIME: 8 minutes] 

Investigating the Impact of a Low-Fat Diet on Quality of Life and Symptom Management in MS: Vijayshree Yadav, MD, MCR, FANA, FAAN

Patients with multiple sclerosis who presented with high-stress maintained their stress management practice through later protocol sessions, according to a study a recent study.

Stress Management Protocol Reduces Depression and Anxiety in Patients With MS: Amy Sullivan, MD

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

Twitter

LinkedIN

Spotlight

Ataxia

CMSC 2023

NMOSD

Narcolepsy

Parkinson Disease

SLEEP 2023

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1rem

Authors

The professor of neurology at Washington University in St. Louis offered an overview of the State of the Science Summit that was held on November 3, 2022, featuring a panel of expert clinicians. [WATCH TIME: 3 minutes]

Choosing DMTs and Ongoing Debates in Multiple Sclerosis: Robert T. Naismith, MD

Impact of Results From the COVID-19 in MS Global Data-Sharing Initiative 

COVID-19 in MS Global Data-Sharing Initiative Anti-CD20 Therapy Results 

CLARITY Extension Trial: Disability Improvement With Cladribine

Chief Endpoints and Potential Significance: Phase 3b OLIKOS Trial

Ofatumumab vs Teriflunomide: Phase 3 ASCLEPIOS I/II Open-Label Extension Study

Key Takeaways from the 8th ACTRIMS-ECTRIMS 2020 Meeting

Ozanimod Compared to Teriflunomide Utilizing Statistical Matching

OPTIMUM Phase 3 Trial: Ponesimod’s Cardiac Safety Data

OLKIOS Phase 3b Trial: Pivotal Endpoints and Potential Significance

Phase 3 ASCLEPIOS I/II Open-Label Extension Study: Ofatumumab vs Teriflunomide 

Takeaways From ACTRIMS-ECTRIMS 2020 Meeting

Rationale for Selected Dosing Regimen of Evobrutinib in Phase 3 Studies 

OPTIMUM: Ponesimod Superiority in MRI-based Outcomes in RRMS

OLKIOS: Looking at Ofatumumab’s Continued Efficacy

Ofatumumab vs Teriflunomide: ASCLEPIOS I/II RMS Trials

Robert Naismith, MD

Articles